DNTH Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Dianthus Therapeutics Inc (DNTH) is not a strong buy at this moment for a beginner investor with a long-term strategy. While the stock has shown positive momentum recently and analysts have raised price targets, the lack of significant trading signals, weak financial performance, and neutral sentiment from hedge funds and insiders suggest that waiting for more clarity on the company's growth trajectory and market catalysts would be prudent.
The MACD is negative and contracting (-0.58), indicating bearish momentum. RSI is neutral at 53.043, and moving averages are converging, suggesting indecision in the market. The stock is trading near its pivot point (49.392), with resistance at 52.33 and support at 46.454.
Analysts have raised price targets significantly, with Oppenheimer setting a target of $125, citing potential superiority of the company's products and substantial value creation ahead. The stock has gained 28% YTD, showing strong momentum.
Net income remains negative, and EPS is still in the red. There is no recent news or significant insider or hedge fund activity to suggest strong confidence in the stock.
In Q3 2025, revenue dropped significantly (-81.77% YoY) to $396,000. However, net income improved to -$36.77M (up 46.04% YoY), and EPS increased to -0.97 (up 31.08% YoY). Gross margin remains at 100%, but overall financials indicate a struggling company.
Analysts are bullish on DNTH, with Wedbush, Oppenheimer, and Truist raising price targets significantly. The highest target is $125 by Oppenheimer, citing potential market superiority and value creation. However, these targets are based on future potential rather than current performance.
